Nubeqa Bayer Australia Ltd
Product name
Nubeqa
Sponsor
Accepted date
Dec-2024
Active ingredients
darolutamide
Proposed indication
Nubeqa is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer (cancer that has spread from the prostate to other parts of the body but is still sensitive to treatment).
Application type
C (new indication)
Publication date
Dec-2024